The gene synthesis service is developed in the biotechnology industry. As a brief introduction to the synthesis of DNA sequences has been developed since the early 1970s and from the late 90s this practice began to be commercialized. Then the demand for synthetic genes investment is attracted.

In the gene synthesis production process is given by the combination of two types of processes, the process design and intermittent production process, the first is characterized by customizing the high and low volume production. Actually the production flow is very low compared to other process such as mass production, so each unit is made as a single item. The second is characterized by a flexible flow production, with a high customization and low volume, but in the latter production volumes are not as low as in the first.

It is intended that the synthetic gene is a combination of both, for each sequence, or product, measurement is made to the customers needs, with a high specification, customized sequences are created from modeling the customer, at the same time production flow streams to different clients operates a flow somewhat more flexible, since each delivery can be operated in parallel, and when working with known gene sequences, the production of such sequences will be simpler, because the parameters stored in the system will be known to the technicians, so that it can increase the production of said sequences.

The branch of gene synthesis involves a multi-step process; first, the customer must plan the DNA sequence for the gene to be synthesized. Companies usually follow a series of steps including product planning for each ordered sequence. After the synthesis is carried out or gene oligos; genes are amplified vector and performing a quality control In terms of industry, the first formal industries gene synthesis was founded in 1999. Following competition and improved technologies synthesis rates have been declining, depending on the gene that is ordered by their sequence the price increases or decreases, although in an approximate amount of production has an approximate price of 30 cents per nucleotide.

According to economic segmentation, our customers are looking for prices that are within a range of medium-low to medium-high. The clients are mainly limited by budgets to the research work, and for the funds distributed to this area, either by the government or by the private sector.

They are customers who need personalized attention, as each project requires a specialized product; and they have to meet with non-negotiable very established waiting times.

For our product, the buying criteria chosen segment is based primarily on price, quality and speed of delivery. Kuxtal Biotech will have a nationally competitive price and allow customers to have the product quickly. Customers will receive special attention and exclusive, ensuring a high degree of attention to the purity of the product and its ability to meet the needs of the client. In addition the product delivery will be less time than set by the competition

One of the opportunities offered by the industry is that the synthesis of genes is seen from the fact that statistically genes providing is centralized European countries and the United States, about 10% of all orders worldwide comes from the above countries. Of that 10% more demand markets are Asians.

As mentioned, there is a competitive advantage with other international companies in Mexico, and almost of production genes is close to zero, which in addition to the location, besides if the investment would be in Mexico, we can guarantee the growth of biotechnology in the coming years, which would increase the number of potential customers for this business project. An example is the project to launch a biotech cluster in the country located in the state of Querétaro. Thus the scope of genes to develop products or can be viewed driven once the cluster is established in the geographical area of the state, all, according to the Economist newspaper.

This market is in different states around Mexico, mainly in those with high technological development. However, don't rule out the possibility of working with some clients located in other countries.

In 2007 there were already about 50 companies worldwide, with a production of around 50,000 per year or 2000 genes and private sector companies producing between 10-2000 orders per month. Assuming that this number will remain constant, or that the price begins to fall for the economic boost to this sector and emerging competition, world output could even double by the year 2015. Orders normal genes have a size ranging between 500 and 2000 nucleotides, although longer synthesis have been reported around 35,000 genes bases in length. Currently some companies engaged in the synthesis of genes have earnings of about $ 2 million per year, allowing them to survive, it is expected that within a few years by automating processes gains will be greater, for it one of the key is to have good relations with customers. As mentioned above one of the barriers currently in gene synthesis is the full automation of processes, because part of the gene synthesis procedure involves manual techniques, sometimes involving human error. Another barrier is obtaining licenses to export genes by the "dual use genes", so companies need to invest time and money in getting this permission.